NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

纳斯达克 · USD

CDT Equity Inc. (CDTTW) 股票分析

CDT Equity Inc.（CDTTW）是在纳斯达克上市的股票，以美元交易。

CDTTW

$0.01

−$0.00 (−1.85%)

2026年9月3日 · 收盘

这是一只衍生品——CDT Equity Inc.（CDTT）普通股的认股权证。

发行人的基本面数据显示在发行人页面，而非本页。

价格走势

悬停查看每日收盘价。虚线表示区间起始价。

CDTTW 关键统计数据

数据截至2026年9月3日
交易
开盘价
$0.01
前收盘价
$0.01
当日波动区间
0.01–0.01
52周波动区间
0.01–0.01
成交量
15.11K
Beta系数股价相对大盘的波动幅度。1.0与大盘同步，高于1.0波动更大，低于1.0更小。
1.45

仅显示公司披露的指标。 数据由Yahoo Finance通过yfinance提供。每日更新。

CDTTW 历年回报率

历年回报率根据每日收盘价计算。 不完整年度以浅色显示并标有星号。

年份回报率
2026 (不完整年度)−3.64%
2025 (不完整年度)+0.00%

数据截至2026年9月3日。

最新新闻

新闻由第三方来源提供。不构成投资建议。

关于CDT Equity Inc.

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

公司简介以英文显示。

访问官网 →